Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant Recipients

This study is ongoing, but not recruiting participants.

Sponsored by:	The Cleveland Clinic
Information provided by:	The Cleveland Clinic
ClinicalTrials.gov Identifier:	NCT00137748

Purpose

This is a randomized controlled trial of CMV-Ig in lung transplant recipients at the Cleveland Clinic Foundation who are hypogammaglobulinemic.

Condition	Intervention	Phase
Hypogammaglobulinemia	Drug: CMV-Ig	Phase II Phase III

MedlinePlus related topics: Cytomegalovirus Infections Lung Transplantation

Study Type:	Interventional
Study Design:	Prevention, Randomized, Open Label, Placebo Control, Single Group Assignment, Safety/Efficacy Study
Official Title:	Does Replacement With CMVIG in Hypogammaglobulinemic Patients Decrease the Rate of Opportunistic Infections and Chronic Rejection?

Further study details as provided by The Cleveland Clinic:

Primary Outcome Measures:

Secondary Outcome Measures:

Estimated Enrollment:	50
Study Start Date:	January 2001
Estimated Study Completion Date:	January 2006

Detailed Description:

This is a randomized controlled trial of CMV-Ig in lung transplant recipients at the Cleveland Clinic Foundation who are hypogammaglobulinemic.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00137748

Locations

United States, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195

Sponsors and Collaborators

The Cleveland Clinic

Investigators

Principal Investigator:

Jeff T Chapman, MD

The Cleveland Clinic

More Information

Study ID Numbers:	IRB2953
Study First Received:	August 29, 2005
Last Updated:	December 12, 2005
ClinicalTrials.gov Identifier:	NCT00137748
Health Authority:	United States: Institutional Review Board

Keywords provided by The Cleveland Clinic:

Lung transplantation

Study placed in the following topic categories:

Lymphatic Diseases
Opportunistic Infections
Agammaglobulinemia
Hematologic Diseases
Blood Protein Disorders

Cytomegalovirus Infections
Lymphoproliferative Disorders
Cytomegalovirus
Immunologic Deficiency Syndromes

Additional relevant MeSH terms:

Immune System Diseases

ClinicalTrials.gov processed this record on January 16, 2009